

Marta Chesi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4322763/publications.pdf>

Version: 2024-02-01

60
papers

6,221
citations

293460

24
h-index

232693

48
g-index

62
all docs

62
docs citations

62
times ranked

11948
citing authors

#	ARTICLE	IF	CITATIONS
1	Transplantation of autologous bone marrow pre-loaded <i>ex vivo</i> with oncolytic myxoma virus is efficacious against drug-resistant $V\lambda^*$ MYC mouse myeloma. <i>Oncotarget</i> , 2022, 13, 490-504.	0.8	2
2	Expression of <i>Nras</i> <i>Q61R</i> and <i>MYC</i> transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. <i>Blood</i> , 2021, 137, 61-74.	0.6	21
3	Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 354-369.	2.6	37
4	Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression. <i>Nature Communications</i> , 2021, 12, 6322.	5.8	12
5	Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma. <i>Blood</i> , 2021, 138, 1593-1593.	0.6	0
6	Aberrant CDK7 Activity Drives the Cell Cycle and Transcriptional Dysregulation to Support Multiple Myeloma Growth: An Attractive Molecular Vulnerability. <i>Blood</i> , 2021, 138, 2687-2687.	0.6	0
7	Selective Cell State in the Clonally Expanded T-Cell Compartment of $V\lambda^*$ MYC Mice Responding to Treatment with Checkpoint Inhibitors. <i>Blood</i> , 2021, 138, 1581-1581.	0.6	0
8	Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination. <i>Leukemia</i> , 2020, 34, 245-256.	3.3	38
9	MYC dysregulation in the progression of multiple myeloma. <i>Leukemia</i> , 2020, 34, 322-326.	3.3	108
10	Monosomic Loss of MIR15A/MIR16-1 Is a Driver of Multiple Myeloma Proliferation and Disease Progression. <i>Blood Cancer Discovery</i> , 2020, 1, 68-81.	2.6	24
11	Identification of PIKfyve kinase as a target in multiple myeloma. <i>Haematologica</i> , 2020, 105, 1641-1649.	1.7	25
12	Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition. <i>Blood</i> , 2020, 136, 1-2.	0.6	0
13	Monosomic Loss of MIR15A/MIR16-1 Is a Driver of Multiple Myeloma Proliferation and Disease Progression. <i>Blood Cancer Discovery</i> , 2020, 1, 68-81.	2.6	0
14	Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model. <i>Blood Advances</i> , 2019, 3, 797-812.	2.5	22
15	Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma. <i>Leukemia</i> , 2019, 33, 1011-1022.	3.3	37
16	Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model. <i>JCI Insight</i> , 2019, 4, .	2.3	20
17	MiR-16 regulates crosstalk in NF- κ B tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. <i>JCI Insight</i> , 2019, 4, .	2.3	33
18	Myeloma Cells Addicted to Glutamine for Biomass Production Are Sensitive to Lenalidomide. <i>Blood</i> , 2019, 134, 4410-4410.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma. <i>Blood</i> , 2019, 134, 3059-3059.	0.6	1
20	Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment. <i>Cancer Cell</i> , 2018, 33, 634-648.e5.	7.7	163
21	Importin- β 2 and exportin-5 are strong biomarkers of productive reoviral infection of cancer cells. <i>Annals of Diagnostic Pathology</i> , 2018, 32, 28-34.	0.6	2
22	Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. <i>Nature Communications</i> , 2018, 9, 4832.	5.8	144
23	Antigen-mediated regulation in monoclonal gammopathies and myeloma. <i>JCI Insight</i> , 2018, 3, .	2.3	43
24	Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. <i>Journal of Clinical Investigation</i> , 2018, 128, 2487-2499.	3.9	80
25	Bone marrow transplantation generates T cell-dependent control of myeloma in mice. <i>Journal of Clinical Investigation</i> , 2018, 129, 106-121.	3.9	49
26	A Single-Cell Transcriptional Analysis of Tumour Cells and the Immune Microenvironment during Disease Evolution in a Transgenic Mouse Model of Myeloma. <i>Blood</i> , 2018, 132, 56-56.	0.6	2
27	Donor T Cells Maintain Myeloma-Immune Equilibrium after Autologous Stem Cell Transplantation and Concurrent Immunotherapy Promotes Cure. <i>Blood</i> , 2018, 132, 2031-2031.	0.6	0
28	Reconstructing the Clonal and Mutational Architecture of Myeloma through Avian Leukosis Virus (ALV)-Mediated Genome Editing. <i>Blood</i> , 2018, 132, 4480-4480.	0.6	0
29	Mice Expressing MYC and NrasQ61R in Germinal Center B Cells Develop Highly Aggressive Multiple Myeloma. <i>Blood</i> , 2018, 132, 1006-1006.	0.6	3
30	Antibodies Create Killer Bonds in Myeloma. <i>Cancer Cell</i> , 2017, 31, 305-307.	7.7	2
31	Multiple myeloma cells' capacity to decompose H ₂ O ₂ determines lenalidomide sensitivity. <i>Blood</i> , 2017, 129, 991-1007.	0.6	33
32	Promiscuous mechanisms underlie the antitumor effects of thalidomide analogs. <i>Nature Medicine</i> , 2016, 22, 706-707.	15.2	5
33	Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2016, 91, E504-E505.	2.0	6
34	IAP antagonists induce anti-tumor immunity in multiple myeloma. <i>Nature Medicine</i> , 2016, 22, 1411-1420.	15.2	133
35	Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. <i>Onc Immunology</i> , 2015, 4, e1008850.	2.1	27
36	Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. <i>Cancer Immunology Research</i> , 2015, 3, 881-890.	1.6	24

#	ARTICLE	IF	CITATIONS
37	Immunosurveillance and therapy of multiple myeloma are CD226 dependent. Journal of Clinical Investigation, 2015, 125, 2077-2089.	3.9	111
38	Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. Nature Communications, 2015, 6, 8428.	5.8	53
39	UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression. Oncotarget, 2015, 6, 40704-40718.	0.8	39
40	TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood, 2014, 123, 3305-3315.	0.6	89
41	Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia, 2014, 28, 1725-1735.	3.3	221
42	Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. Leukemia Research, 2014, 38, 948-954.	0.4	14
43	Inhibition Of RNA Polymerase I Transcription By CX-5461 As a Therapeutic Strategy For The Cancer-Specific Activation Of p53 In Highly Refractory Haematological Malignancies. Blood, 2013, 122, 3941-3941.	0.6	4
44	Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood, 2012, 120, 376-385.	0.6	174
45	PARP Inhibition (OLAPARIB) Enhance Melphalan and Nutlin-3a Sensitivity in TP53 Positive Multiple Myeloma. Blood, 2012, 120, 1846-1846.	0.6	1
46	Promiscuous Cryptic Rearrangements of the MYC Locus Cis-Dysregulate MYC Expression and Are Present in the Majority of Patients with Hyperdiploid Myeloma. Blood, 2012, 120, 724-724.	0.6	1
47	Genome Wide Studies in Multiple Myeloma Identify XPO1/CRM-1 As a Critical Target Validated Using the Selective Inhibitor of Nuclear Export (SINE) KPT-276. Blood, 2012, 120, 573-573.	0.6	1
48	Many Multiple Myelomas: Making More of the Molecular Mayhem. Hematology American Society of Hematology Education Program, 2011, 2011, 344-353.	0.9	46
49	BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. Cell, 2011, 146, 904-917.	13.5	2,432
50	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. Blood, 2011, 118, 1409-1409.	0.6	0
51	Examining Measures of Proliferation for Use in Risk Stratification of Myeloma. Blood, 2011, 118, 5093-5093.	0.6	0
52	The Murine V λ *MYC Myeloma Shares Defining Genetic Lesions with Human Multiple Myeloma. Blood, 2009, 114, 1808-1808.	0.6	2
53	AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies. Cancer Cell, 2008, 13, 167-180.	7.7	322
54	Promiscuous Mutations Activate the Noncanonical NF- κ B Pathway in Multiple Myeloma. Cancer Cell, 2007, 12, 131-144.	7.7	941

#	ARTICLE	IF	CITATIONS
55	Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).. Blood, 2007, 110, 241-241.	0.6	1
56	A Novel Transgenic Mouse Model of Multiple Myeloma Reliably Predicts Drug Response.. Blood, 2006, 108, 241-241.	0.6	1
57	High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.. Blood, 2006, 108, 3407-3407.	0.6	0
58	Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes.. Blood, 2005, 106, 3381-3381.	0.6	0
59	The Multiple Myeloma SET Domain (MMSET) Protein Is a Histone H3 and H4 Methyltransferase with Properties of a Transcriptional Co-Repressor.. Blood, 2005, 106, 358-358.	0.6	0
60	Genetics and Cytogenetics of Multiple Myeloma. Cancer Research, 2004, 64, 1546-1558.	0.4	642